The influence of local IOP-lowering therapy on the anterior segment tissues and outcome of glaucoma filtering surgery

Cover Page

Abstract


Nowadays, a wide choice of local IOP-lowering medications allows ensuring a successful intraocular pressure compensation and primary open angle glaucoma stabilization. However, taking into consideration a long term action of drugs on the ocular surface, even without clinical manifestations there is a direct inflammatory cells’ activation with mixed toxic and allergic changes, which is confirmed by histology, immune-histology, and impression cytology methods. Such chronic sub-clinical inflammation represent a potential risk of excessive fibroblast proliferation with subsequent rapid postoperative scarring of new outflow pathways and atypical filtration bleb formation. It is shown that there is a clear relationship between number of glaucoma drugs used, treatment duration, intensity of conjunctival infiltration with inflammatory cells and fibroblasts, and risk of episcleral fibrosis and subconjunctival scarring during post-op period.


Sergej Yu. Petrov

Scientific Research Institute of Eye Diseases

Author for correspondence.
Email: post@glaucomajournal.ru

Russian Federation, Moscow

PhD, leading research associate, Glaucoma Department

Dzhamilya N. Lovpache

Moscow Helmholtz Research Institute of Eye Diseases

Email: dlovpache@mail.ru

Russian Federation, Moscow

PhD, senior research associate, Glaucoma Department

Igor' A. Loskutov

Scientific Clinical Center of Russian Railways

Email: loskoutigor@mail.ru

Russian Federation, Moscow

Professor, DMedSc, Head of the Clinical Center

Daria M. Safonova

Scientific Research Institute of Eye Diseases

Email: dmsafonova@gmail.com

Russian Federation, Moscow

PhD, Junior Research Associate, Phacoemulsification and Intraocular Correction Department

  • Астахов С.Ю., Астахов Ю.С., Ткаченко Н.В. Изменения конъюнктивы и роговицы у пациентов с глаукомой на фоне местной гипотензивной терапии // Новости глаукомы. – 2010. – № 1. – С. 16. [Astahov SJu, Astahov JuS, Tkachenko NV. Izmenenija kon’junktivy i rogovicy u pacientov s glaukomoj na fone mestnoj gipotenzivnoj terapii. Novosti glaukomy. 2010;(1):16. (In Russ.)]
  • Астахов С.Ю., Грабовецкий В.Р., Нефедова Д.М., Ткаченко Н.В. Преимущества и недостатки гипотензивных капель без консерванта // Офтальмологические ведомости. – 2011. – Т 4. – № 2. – С. 95–98. [Astahov SJu, Graboveckij VR, Nefedova DM, Tkachenko NV. Preimushhestva i nedostatki gipotenzivnyh kapel’ bez konservanta. Oftal’mologicheskie vedomosti. 2011;4(2):95-98. (In Russ.)]
  • Астахов С.Ю., Доморад А.А., Ткаченко Н.В., Яковлева О.М. Эффективность и безопасность гипотензивных препаратов // Офтальмологические ведомости. – 2012. – Т. 5. – № 2. – С. 72–76. [Astahov SJu, Domorad AA, Tkachenko NV, Jakovleva OM. Jeffektivnost’ i bezopasnost’ gipotenzivnyh preparatov. Oftal’mologicheskie vedomosti. 2012;5(2):72-76. (In Russ.)]
  • Астахов С.Ю., Ткаченко Н.В. Первый опыт применения бета-блокаторов без консерванта // Офтальмологические ведомости. – 2010. – Т. 3. – № 2. – С. 66–77. [Astahov SJu, Tkachenko NV. Pervyj opyt primenenija beta-blokatorov bez konservanta. Oftal’mologicheskie vedomosti. 2010;3(2):66-77. (In Russ.)]
  • Астахов Ю.С., Логинов Г.Н. Исследование эффективности безопасности комбинации Азопта и Бетоптика у пациентов с первичной открытоугольной глаукомой // Клиническая фармакология и терапия. – 2003. – № 1. – С. 26. [Astahov JuS, Loginov GN. Issledovanie jeffektivnosti bezopasnosti kombinacii Azopta i Betoptika u pacientov s pervichnoj otkrytougol’noj glaukomoj. Klinicheskaja farmakologija i terapija. 2003;(1):26. (In Russ.)]
  • Краснов М.М., Зиангирова Г.Г., Шмырева В.Ф., Акберова С.И. Клинико-морфологические характеристики микроциркуляции конъюнктивы и радужки при открытоугольной глаукоме // Вестник офтальмологии. – 1993. – Т. 109. – № 5. – С. 7–10. [Krasnov MM, Ziangirova GG, Shmyreva VF, Akberova SI. Kliniko-morfologicheskie harakteristiki mikrocirkuljacii kon’’junktivy i raduzhki pri otkrytougol’noj glaukome. Vestnik oftal’mologii. 1993;109(5):7-10. (In Russ.)]
  • Малаханова Н.А. Изменения конъюнктивы при глаукоме // Вестник офтальмологии. – 1966. – Т. 79. – № 3. – С. 70–73. [Malahanova NA. Izmenenija kon’’junktivy pri glaukome. Vestnik oftal’mologii. 1966;79(3):70-73. (In Russ.)]
  • Фёдоров С.Н., Ронкина Т.И., Васин В.И. Клинико-морфологическое сравнение состояния кровеносных сосудов в дренажной зоне склеры и радужной оболочки при различных стадиях открытоугольной глаукомы // Офтальмологический журнал. – 1981. – Т. 36. – № 1. – С. 12–16. [Fedorov SN, Ronkina TI, Vasin VI. Kliniko-morfologicheskoe sravnenie sostojanija krovenosnyh sosudov v drenazhnoj zone sklery i raduzhnoj obolochki pri razlichnyh stadijah otkrytougol’noj glaukomoj. Oftal’mologicheskij zhurnal. 1981;36(1):12-16. (In Russ.)]
  • Amar N, Labbe A, Hamard P, et al. Filtering blebs and aqueous pathway: An immunocytological and in vivo confocal microscopy study. Ophthalmology. 2008;115(7):1154-1161. doi: 10.1016/j.ophtha.2007.10.024.
  • Astakhov YS, Astakhov SY, Lisochkina AB. Assessment of dry eye signs and symptoms and ocular tolerance of a preservative-free lacrimal substitute (Hylabak(R)) versus a preserved lacrimal substitute (Systane(R)) used for 3 months in patients after LASIK. Clinical Ophthalmology. 2013;7:2289-2297. doi: 10.2147/OPTH.S50446.
  • Baudouin C, Garcher C, Haouat N, et al. Expression of inflammatory membrane markers by conjunctival cells in chronically treated patients with glaucoma. Ophthalmology. 1994;101(3):454-460.
  • Baudouin C, Hamard P, Liang H, et al. Conjunctival epithelial cell expression of interleukins and inflammatory markers in glaucoma patients treated over the long term. Ophthalmology. 2004;111(12):2186-2192. doi: 10.1016/j.preteyeres. 2010.03.001.
  • Baudouin C, Labbe A, Liang H, et al. Preservatives in eyedrops: the good, the bad and the ugly. Prog Retin Eye Res. 2010;29(4):312-334. doi: 10.1016/j.preteyeres. 2010.03.001.
  • Baudouin C, Liang H, Hamard P, et al. The ocular surface of glaucoma patients treated over the long term expresses inflammatory markers related to both T-helper 1 and T-helper 2 pathways. Ophthalmology. 2008;115(1):109-115. doi: 10.1016/j.ophtha.2007.01.036.
  • Baudouin C, Nordmann JP, Denis P, et al. Efficacy of indomethacin 0.1% and fluorometholone 0.1% on conjunctival inflammation following chronic application of antiglaucomatous drugs. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 2002;240(11):929-935.
  • Baudouin C, Pisella PJ, Fillacier K, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106(3):556-563.
  • Brandt JD. Does benzalkonium chloride cause cataract? Archives of Ophthalmology. 2003;121(6):892-893.
  • Brandt JD, Wittpenn JR, Katz LJ, et al. Conjunctival impression cytology in patients with glaucoma using long-term topical medication. Am J Ophthalmol. 1991;112(3):297-301.
  • Breusegem C, Spielberg L, Van Ginderdeuren R, et al. Preoperative nonsteroidal anti-inflammatory drug or steroid and outcomes after trabeculectomy: a randomized controlled trial. Ophthalmology. 2010;117(7):1324-1330. doi: 10.1016/j.ophtha.2009.11.038.
  • Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva. Journal of Glaucoma. 2001;10(3):237-249.
  • Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. I. The conjunctival cell profile. Archives of Ophthalmology. 1994;112(11):1437-1445.
  • Broadway DC, Grierson I, O’Brien C, Hitchings RA. Adverse effects of topical antiglaucoma medication. II. The outcome of filtration surgery. Archives of Ophthalmology. 1994;112(11):1446-1454.
  • Broadway DC, Grierson I, Sturmer J, Hitchings RA. Reversal of topical antiglaucoma medication effects on the conjunctiva. Archives of Ophthalmology. 1996;114(3):262-267.
  • Erb C, Gast U, Schremmer D. German register for glaucoma patients with dry eye. I. Basic outcome with respect to dry eye. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 2008;246(11):1593-1601.
  • European. European Glaucoma Society: Terminology and Guidelines for Glaucoma. 3rd edition. Savona, Italy Editrice Dogma; 2008.
  • Gedde SJ, Schiffman JC, Feuer WJ, et al. Three-year follow-up of the tube versus trabeculectomy study. Am J Ophthalmol. 2009;148(5):670-684. doi: 10.1016/j.ajo.2009.06.018.
  • Hong S, Lee CS, Seo KY, et al. Effects of topical antiglaucoma application on conjunctival impression cytology specimens. Am J Ophthalmol. 2006;142(1):185-186.
  • Hutchinson AK, Grossniklaus HE, Brown RH, et al. Clinicopathologic features of excised mitomycin filtering blebs. Archives of Ophthalmology. 1994;112(1):74-79.
  • Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol. 2007;17(3):341-349.
  • Lama PJ, Fechtner RD. Antifibrotics and wound healing in glaucoma surgery. Survey of Ophthalmology. 2003;48(3):314-346.
  • Lavin MJ, Wormald RP, Migdal CS, Hitchings RA. The influence of prior therapy on the success of trabeculectomy. Archives of Ophthalmology. 1990;108(11):1543-1548.
  • Leung EW, Medeiros FA, Weinreb RN. Prevalence of ocular surface disease in glaucoma patients. Journal of Glaucoma. 2008;17(5):350-355. doi: 10.1097/IJG.0b013e31815c5f4f.
  • Nuzzi R, Vercelli A, Finazzo C, Cracco C. Conjunctiva and subconjunctival tissue in primary open-angle glaucoma after long-term topical treatment: an immunohistochemical and ultrastructural study. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle. Ophthalmologie. 1995;233(3):154-162.
  • Picht G, Grehn F. Classification of filtering blebs in trabeculectomy: biomicroscopy and functionality. Curr Opin Ophthalmol. 1998;9(2):2-8.
  • Pisella PJ, Debbasch C, Hamard P, et al. Conjunctival proinflammatory and proapoptotic effects of latanoprost and preserved and unpreserved timolol: an ex vivo and in vitro study. Investigative Ophthalmology & Visual Science. 2004;45(5):1360-1368.
  • Pisella PJ, Pouliquen P, Baudouin C. Prevalence of ocular symptoms and signs with preserved and preservative free glaucoma medication. Br J Ophthalmol. 2002;86(4):418-423.
  • Powers TP, Stewart WC, Stroman GA. Ultrastructural features of filtration blebs with different clinical appearances. Ophthalmic Surgery and Lasers. 1996;27(9):790-794.
  • Pozarowska D, Toczolowski J, Wozniak F. [The evaluation of morphological status of bulbar conjunctiva after long-term antiglaucoma drug therapy]. Klinika Oczna. 1999;101(6): 455-458.
  • Sacu S, Rainer G, Findl O, Georgopoulos M, Vass C. Correlation between the early morphological appearance of filtering blebs and outcome of trabeculectomy with mitomycin C. Journal of Glaucoma. 2003;12(5):430-435.
  • Schwab IR, Linberg JV, Gioia VM, et al. Foreshortening of the inferior conjunctival fornix associated with chronic glaucoma medications. Ophthalmology. 1992;99(2):197-202. doi: 10.1016/S0161-6420(92)32001-9.
  • Sherwood MB, Grierson I, Millar L, Hitchings RA. Long-term morphologic effects of antiglaucoma drugs on the conjunctiva and Tenon’s capsule in glaucomatous patients. Ophthalmology. 1989;96(3):327-335. doi: 10.1016/S0161-6420(89)32888-0.
  • Shields MB, Scroggs MW, Sloop CM, Simmons RB. Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin C. Am J Ophthalmol. 1993;116(6):673-683. doi: 10.1016/S0002-9394(14)73465-8.
  • Souchier M, Buron N, Lafontaine PO, et al. Trefoil factor family 1, MUC5AC and human leucocyte antigen-DR expression by conjunctival cells in patients with glaucoma treated with chronic drugs: could these markers predict the success of glaucoma surgery? Br J Ophthalmol. 2006;90(11):1366-1369. doi: 10.1136/bjo.2006.094912.
  • Thorne JE, Anhalt GJ, Jabs DA. Mucous membrane pemphigoid and pseudopemphigoid. Ophthalmology. 2004;111(1):45-52. doi: 10.1016/j.ophtha.2003.03.001.
  • Uusitalo H, Chen E, Pfeiffer N, et al. Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication. Acta Ophthalmologica. 2010;88(3):329-336. doi: 10.1111/j.1755-3768.2010.01907.x.
  • Vesti E. Filtering blebs: follow up of trabeculectomy. Ophthalmic Surgery. 1993;24(4):249-255.

Views

Abstract - 181

PDF (Russian) - 60

PlumX


Copyright (c) 2017 Petrov S.Y., Lovpache D.N., Loskutov I.A., Safonova D.M.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.